300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Colombia
Guernsey
Cameroon
Armenia
China
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Seychelles
Moldova
Botswana
South Africa
Paraguay
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
Canada
India
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
SPRIM Global Investments, VC Fund

SPRIM Global Investments

VC Fund

New York, United States

SPRIM Global Investments is a privately held investment company. SGI was established in 2008 following the global expansion of SPRIM Consulting & Services business.SPRIM Global Investments leverages the funnel of SPRIM’s sourcing, screening and selection processes across the globe to identify and invest in high potential health solutions. Wefind dynamic young companies proposing innovative offerings and help them to accelerate their growth. These startups can, in turn, leverage the SPRIM network, enabling them to fast-track their development. Our portfolio companies have full access to SPRIM’s fellow venture company experts across the globe as well as the company’s investment vehicles.

Total investments:
19
Last investment:
Lead investor:
89%

Last updated:

Industries SPRIM Global Investments invests in

BiotechnologyHealth CareMedical DevicePharmaceuticalTherapeutics

Stages SPRIM Global Investments invests in

Series ADebt FinancingVenture - Series UnknownSeedSeries B

Countries SPRIM Global Investments invests in

AustraliaUnited StatesFranceSwitzerlandItaly

Round sizes

Series A $10M–$22MDebt Financing $500k–$26M

Round size

Series A
$10M–$22M
Debt Financing
$500k–$26M

Investment Focus

Industry

  • Biotechnology 9 (47%)
  • Health Care 6 (32%)
  • Medical Device 4 (21%)
  • Pharmaceutical 4 (21%)
  • Therapeutics 3 (16%)
See all 14 industries →

Stage

  • Series A 5 (26%)
  • Debt Financing 3 (16%)
  • Venture - Series Unknown 2 (11%)
  • Seed 1 (5%)
  • Series B 1 (5%)
See all 10 stages →

Country

  • Australia 3 (16%)
  • United States 3 (16%)
  • France 2 (11%)
  • Switzerland 2 (11%)
  • Italy 1 (5%)
See all 8 countries →

Investments

CompanyDescriptionRoundLinks
Body Vision Medical Body Vision Medical
Body Vision Medical eliminates CT-to-body divergence and provides visual confirmation of tool-in-lesion prior to biopsy, while intraoperative CT imaging and enhanced fluoroscopy provide unparalleled control over diagnostic output. They can be a dedicated intraoperative 3D imaging solution for tool-in-lesion confirmation or a standalone navigationalbronchoscopy platform. Venture - Series Unknown / Aug 06, 2026
NinaMED NinaMED
NinaMED is a healthcare and medical solutions company associated with medical services and technology-enabled healthcare solutions. $10M / Seed / May 13, 2026
ErVimmune ErVimmune
ErVimmune creates novel immunotherapies that target non-conventional tumor antigens that are abnormally expressed in cancer cells and shared by tumors and patients, with a particular emphasis on meeting unmet medical requirements in cold malignancies. $19.9M / Series A / Jan 21, 2026
KAHR medical KAHR medical
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. $10M / Debt Financing / Oct 15, 2025
Vaxxas Vaxxas
Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. $31.8M / Series D / Aug 25, 2025
Vaxxas Vaxxas
Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. $25.9M / Debt Financing / Aug 25, 2025
Azalea Vision Azalea Vision
Azalea Vision is a medical manufacturer designing contact lenses with an active light management system for people with ocular disorders. $10.3M / Series A / Apr 29, 2025
RheumaGen RheumaGen
RheumaGen is a gene-editing technology developing therapeutics to cure rheumatoid arthritis. It offers an HLA gene-editing platform that uses stem-cell-enriched blood to alter DNA to suppress the immune system and stop rheumatoid arthritis's abnormal immune response. $15M / Series A / Jan 09, 2025
CILcare CILcare
CILcare specializes in providing drug solutions for hearing and ear disorders. $42M / Series A / Dec 04, 2024
Doron Therapeutics Doron Therapeutics
Doron Therapeutics is a clinical-stage biotechnology company that has developed intra-articular biologic drugs derived from placental tissue and consistently delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective, and regenerative capabilities pivotal to the progressive and degenerative disease ofosteoarthritis. $11M / Series A / Nov 25, 2024
See all 19 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Colombia
Guernsey
Cameroon
Armenia
China
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Seychelles
Moldova
Botswana
South Africa
Paraguay
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
Canada
India
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does SPRIM Global Investments invest in?

SPRIM Global Investments invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Debt Financing stage. Most of the 19 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does SPRIM Global Investments invest in?

SPRIM Global Investments typically joins rounds of $10M–$22M at Series A and $500k–$26M at Debt Financing. These are whole funding-round sizes, not SPRIM Global Investments's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds SPRIM Global Investments took part in.

When did SPRIM Global Investments last invest?

The most recent investment recorded for SPRIM Global Investments closed in Aug 2026. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
SPRIM Global Investments SPRIM Global Investments Find emails